Article
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Cancer immunology, immunotherapy : CII - 1 Nov 2018
Weber Alexander N R, Cardona Gloria Yamel, Çınar Özcan, Reinhardt H Christian, Pezzutto Antonio, Wolz Olaf-Oliver
Abstract excerpt
Oncogenic MYD88 mutations, most notably the Leu 265 Pro (L265P) mutation, were recently identified as potential driver mutations in various B-cell non-Hodgkin Lymphomas (NHLs). The L265P mutation is now thought to be common to virtually all NHLs and occurs in between 4 and 90% of cases, depending on the entity. Since it is tumor-specific, the mutation, and the pathways it regulates, might serve as advantageous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.